Because TRAIL selectively induces apoptosis in cancer cells, clinical trials were conducted to test the efficacy of TRAIL and agonist antibodies targeting death receptors in cancer patients (Table 1) [7,92]. The gene discussed is TNFSF10; the disease is cancer.